| Akouos is a genetic medicine company, engaged in developing gene therapies to restore, improve, and preserve physiologic hearing for individuals who live with disabling hearing loss. Co. has a genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus used in gene therapy, known as adeno-associated virus, and a delivery approach. Co. is developing its product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of etiology, such as AK-antiVEGF for vestibular schwannoma. The AKUS YTD return is shown above.
The YTD Return on the AKUS YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AKUS YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AKUS YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.